Search clinical trials for: ALXN2050 MR Prototype Tablet

Total 40 results

Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Healthy

United Kingdom
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
Eidos Therapeutics, a BridgeBio company

Completed

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM)

Heart Diseases | Amyloidosis | Cardiomyopathies | Transthyretin Amyloidosis | Amyloid Cardiomyopathy

United States, Netherlands, Ireland, Canada, Italy, Spain, Belgium, New Zealand, Israel, Australia, Portugal, Brazil, Poland, Czechia, Denmark, Greece, Korea, Republic of, United Kingdom
Genentech, Inc.

Completed

Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810

Healthy Volunteer

United Kingdom
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants

Healthy

New Zealand
Lyndra Inc.

Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Healthy | Gastric Retention

United Kingdom
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Alexion Pharmaceuticals
Celerion

Completed

Study of the Metabolism of Danicopan in Healthy Adults

Healthy

United States
Neurogen Corporation

Terminated

Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States
Disphar International B.V.

Withdrawn

Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets

Comparative Bioavailability

Jordan
Neurogen Corporation

Terminated

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

Early Parkinson Disease

United States
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Kubota Vision Inc.

Completed

Effects of Projected Peripheral Defocus on Ocular Biometrics

Myopia

United States
Medicines for Malaria Venture
Quotient Clinical

Completed

Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets

Malaria

United Kingdom
Indivior Inc.

Completed

A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers

Healthy Volunteers

United Kingdom
Lung Biotechnology PBC

Completed

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Czechia, Germany, Ireland, Romania
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
MediBeacon

Completed

Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers (ORFM-1B)

Acute Kidney Injury | Glomerular Filtration Rate

United States
Lung Biotechnology PBC

Completed

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Ireland
International Centre for Diarrhoeal Disease Research...
Washington University School of Medicine

Recruiting

Shelf-Stable MDCF-2 for Children With Undernutrition

Undernutrition

Bangladesh
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
GE Healthcare

Completed

Clinical Evaluation of an Integrated PET/MRI System (PET/MR_ZURICH)

Subjects With Clinical Indication for PET/CT

Switzerland
Ferring Pharmaceuticals

Completed

Safety Study of XP12B in Women With Menorrhagia

Menorrhagia | Heavy Menstrual Bleeding

United States
GE Healthcare

Completed

Comparison of 18F FDG PET/CT TO PET MRI (PET/MR US)

Any Condition With a Clinical Indication for PET/CT Exam

United States
Alembic Pharmaceuticals Ltd.

Completed

Single Dose Crossover Comparative Bioavailability Study of Bupropion Hcl MR Tablet 300mg

Bioequivalence

Canada
dora pereira
University of Oxford; University of Cambridge; Bangor University

Completed

Health Economics of the Use of Ferrous Iron Salts in Primary Care in the UK.

Anemia

United Kingdom
NYU Langone Health

Completed

Mapping the Target for the MRgFUS Treatment of Tremor

Parkinson's Disease | Tremor, Essential

United States
Gitte Moos Knudsen

Recruiting

Precision Medicine in the Treatment of Epilepsy (BDE)

Epilepsy

Denmark
H. Lundbeck A/S

Completed

Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women

Healthy Women

United Kingdom
Astellas Pharma Inc

Completed

A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia

Sleep Initiation and Maintenance Disorders

Japan
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Locally Advanced Unresectable Primary Central Chondrosarcoma

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
Mayo Clinic

Recruiting

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Biochemically Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

Stage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical Cancer

United States
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Lung Adenocarcinoma | Stage III Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell Carcinoma | Lung Large Cell Carcinoma

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy; City of Hope National Medical Center and other collaborators

Recruiting

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Metastatic Melanoma | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Advanced Vaginal Adenocarcinoma | Advanced Vaginal Adenosquamous Carcinoma | Advanced Vaginal Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage II Vaginal Cancer AJCC v6 and v7 | Stage III Vaginal Cancer AJCC v6 and v7 | Stage IIIB Cervical... and other conditions

United States

Search clinical trials for: ALXN2050 MR Prototype Tablet

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations